DFP 11207

Drug Profile

DFP 11207

Alternative Names: DFP-11207

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics; Small interfering RNA; Small molecules
  • Mechanism of Action RNA interference; Thymidylate synthase expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Capsule)
  • 01 Apr 2017 Efficacy, pharmacokinetics and adverse events data from a clinical trial presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 09 Dec 2015 Phase-II development for Solid tumours (Late-stage disease) is ongoing in USA (NCT02171221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top